Authorship includes a multidisciplinary group of experts from different institutions and countries in Europe and abroad. Enhancing the feasibility of outpatient daratumumab administration via a split-dosing strategy with initial doses. 2017 Jul 1;28(suppl_4):iv119-iv142. Algorithm for the evaluation of drug hypersensitivity reactions and the role of desensitization for the re-introduction of the first-line medications, when no alternative is available or the alternative does not provide the same benefits or life expectancy as the first line. Model of in vitro mouse mast cells activation and desensitization. Atopic patients are at increased risk for chemotherapy and MoAbs drug allergy and the current patterns of treatment with recurrent and intermittent drug exposures may favor the development of drug allergies. Analysis of patients with epithelial ovarian cancer or fallopian tube carcinoma retreated with cisplatin after the development of a carboplatin allergy. Recommendations for prevention/therapy of acneiform rash, hand-foot syndrome, alopecia, pruritus, paronychia and onycholysis are provided including levels of evidence and grades of recommendation where applicable. Prevention and Management of Dermatological Toxicities Related to Anticancer Agents: ESMO Clinical Practice Guidelines. 66, 265267. It would be worthwhile to evaluate the correlation between other HRD genes and carboplatin hypersensitivity. Oncol. Compared to women without hypersensitivity reactions, women who experienced hypersensitivity reactions had a significantly greater median cycle number (12 vs. 6, P < 0.001, independent sample t-test) and dose (6,816 vs. 3,844 mg, P < 0.001, independent sample t-test). Login to your ESMO account to sign up for ESMO newsletters and receive information about ESMO's scientific and educational resources, events, member benefits. Would you like email updates of new search results? A. Incidence of carboplatin-related hypersensitivity reactions in Japanese patients with gynecologic malignancies. Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly. The overall safety profile was similar between subgroups. Patients should be observed closely for hypersensitivity reactions for a minimum of 30 minutes following each IV iron . General Information | ESMO 2017 However, basophil activation has been observed in patients with a history of severe carboplatin hypersensitivity reaction (Iwamoto et al., 2014). Most anticancer treatments carry a risk for infusion reactions which incidence may increase when different agents are administered concomitantly. J Oncol Pract. (2007). The most commonly exhibited symptom/sign was hypotension (10.7%), followed by anaphylaxis (8.0%) and desaturation (6.7%). Gerber, C. van den Hurk, P. Fernndez-Peas, D. Santini, F. Jahn, K. Jordan on behalf of the ESMO Guidelines Committee These ESMO Clinical Practice Guidelines provide recommendations on the . S M S, Naveen NR, Rao GK, Gopan G, Chopra H, Park MN, Alshahrani MM, Jose J, Emran TB, Kim B. Here, we retrospectively evaluated carboplatin-related hypersensitivity reactions among patients with gynecological cancer (ovarian, fallopian tube, or primary peritoneal cancer) who received carboplatin-containing regimens at a single medical institute in Taiwan. DARMSTADT, Germany, August 31, 2017 /PRNewswire/ --Not intended for UK-based media Data to showcase Merck KGaA, Darmstadt, Germany's strong and d. This review provides insight into the current knowledge of drug allergy and anaphylaxis to cancer and chronic inflammatory diseases drugs, the mechanisms of drug desensitization and its applications to personalized medicine. (2009). Monitor. It would be worthwhile to design a perspective trial that could randomize patients with carboplatin hypersensitivity to receive an alternative regimen without carboplatin. For salvage chemotherapy in the case of recurrent disease, we administered chemotherapeutic regimens including carboplatin with paclitaxel, gemcitabine, or liposomal doxorubicin. Among cases developing carboplatin-related hypersensitivity reactions, the median number of cycles is 912, and the median doses 6,0008,000 mg. Reported risk factors for carboplatin-related hypersensitivity reactions include carboplatin cycle/dose, platinum-free interval, and history of drug allergies (Libra et al., 2003; Confino-Cohen et al., 2005; Schwartz et al., 2007; Koshiba et al., 2009). Via Ginevra 4, 6900 Lugano - CH Copyright 2023 European Society for Medical Oncology All rights reserved worldwide. A prospective single-center study. Ovarian cancer is the leading cause of death from gynecological malignancies (Chiang et al., 2013), with a 5-year survival rate of 46% in the United States (92% when localized, 73% with regional metastases, and 28% with distant metastases) (Siegel et al., 2016). Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used. Pegylated liposomal doxorubicin and carboplatin compared with paclitaxel and carboplatin for patients with platinum-sensitive ovarian cancer in late relapse. (2003). In addition, the development of a new generation of platinum cytotoxic drugs to avoid hypersensitivity reactions is warranted. reported that the majority (93%) of patients with a BRCA1/2 mutation develop carboplatin hypersensitivity, and that BRCA1/2 mutation is an independent risk factor for the development of carboplatin hypersensitivity. doi: 10.1093/annonc/mdx225. ESMO is a Swiss-registered not-for-profit organisation. E. Restuccia: Financial Interests, Personal, Full or part-time Employment: F. Hoffmann-La Roche Ltd.; Financial Interests, Personal, Stocks/Shares: Genentech, Inc; Non-Financial Interests, Personal, Research Grant, Medical writing support: F. Hoffmann-La Roche Ltd. S. Loibl: Financial Interests, Institutional, Advisory Board: AstraZeneca; Financial Interests, Institutional, Advisory Board: AbbVie; Financial Interests, Institutional, Advisory Board: Amgen; Financial Interests, Institutional, Advisory Board: Celgene; Financial Interests, Institutional, Advisory Board: Novartis; Financial Interests, Institutional, Advisory Board: Pfizer; Financial Interests, Institutional, Advisory Board: Roche; Financial Interests, Institutional, Advisory Board: Seattle Genetics; Financial Interests, Institutional, Advisory Board: PriME/ Medscape; Financial Interests, Personal, Invited Speaker: Chugai; Financial Interests, Personal, Research Grant: Teva; Financial Interests, Personal, Research Grant: Vifor; Financial Interests, Institutional, Research Grant: Daiichi-Sankyo; Financial Interests, Institutional, Advisory Board: Lilly; Financial Interests, Institutional, Advisory Board: Samsung; Financial Interests, Institutional, Advisory Board: Eirgenix; Financial Interests, Institutional, Advisory Board: BMS; Financial Interests, Institutional, Advisory Board: Puma; Financial Interests, Personal, Research Grant: Immunomedics; Non-Financial Interests, Personal, Other, Patent EP14153692 .0 pending: Roche; Non-Financial Interests, Personal, Research Grant, Medical writing support: F. Hoffmann-La Roche Ltd.; Financial Interests, Institutional, Advisory Board: MSD. (Moon et al., 2013) BRCA1/2 mutation patients had early-onset carboplatin hypersensitivity at a lower cumulative exposure. Bethesda, MD 20894, Web Policies All funding for this site is provided directly by ESMO. Incidence and intensity of anaphylaxis/hypersensitivity events: Table: 138P. Paclitaxel plus platinum-based chemotherapy vs. conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial. 53, 121122. The PubMed wordmark and PubMed logo are registered trademarks of the U.S. Department of Health and Human Services (HHS). Necessary cookies enable core functionality. The histological type was serous in 381 patients (51.8%) and clear cell in 148 patients (20.1%). Life expectancy for cancer patients allergic and desensitized to carboplatin and non-allergic to, MeSH By delivering the target, Symptoms and signs of hypersensitivity reactions amendable to desensitization. Carboplatin hypersensitivity: evaluation and successful desensitization protocol. Supportive and Palliative Care | ESMO 3, 10 In subsequent trials, 11 - 16 patients were premedicated CA. Disclaimer. Int. Tumori 89, 311313. del Carmen Sancho M, Breslow R, Sloane D, Castells M. Chem Immunol Allergy. -. ESMO is a Swiss-registered not-for-profit organisation. Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel on patients with optimally resected stage III ovarian cancer: a gynecologic oncology group study. Oncol. (2005). ESMO Clinical Practice . Morgan C, Tillett T, Braybrooke J, Ajithkumar T. Lancet Oncol. Please enable it to take advantage of the complete set of features! News, highlights and insights download your copy here. Oncol. Assess for lymphadenopathy, facial or distal extremity swelling (may be signs of drug-induced hypersensitivity syndrome/DRESS). Open. This site uses cookies. Prevention and Treatment of Side Effects of Immunotherapy for Bladder Cancer. (2006). Zhi. Adolescents and Young Adults Working Group, ESMO SIOG Cancer in the Elderly Working Group, Examination & Accreditation Working Group, Real World Data and Digital Health Working Group, Translational Research and Precision Medicine Working Group, ESMO-Magnitude of Clinical Benefit Scale Working Group, Press and Media Affairs Committee and Social Media Working Group, ESMO-MCBS Working Group: Open Call for New Extended Members, ESMO Co-Editors-in-Chief for ESMO Journals Open Call for Members, ESMO Clinical Research Observatory Task Force (ECRO), Notification of 2022 ESMO General Assembly Vote, EnLiST ESMO Adaptation of Line of Systemic Therapy, Cancer Patient Management During the COVID-19 Pandemic, Primary brain tumours in the COVID-19 era, Gastrointestinal cancers: Hepatocellular carcinoma (HCC) in the COVID-19 era, Genitourinary cancers: Urothelial cancer of the bladder in the COVID-19 era, Genitourinary cancers: Renal cell cancer in the COVID-19 era, Genitourinary cancers: Prostate cancer in the COVID-19 era, Gynaecological malignancies: Cervical cancer in the COVID-19 era, Gynaecological malignancies: Endometrial cancer in the COVID-19 era, Haematological malignancies: DLBCL, MCL and Aggressive T-cell lymphoma in the second phase of the COVID-19 pandemic (ESMO-EHA), Haematological malignancies: Hodgkin lymphoma in the second phase of the COVID-19 pandemic (ESMO-EHA), Haematological malignancies: Indolent B-NHL in the second phase of the COVID-19 pandemic (ESMO-EHA), Haematological malignancies: Multiple myeloma in the COVID-19 era, Head and neck cancers in the COVID-19 era, COVID-19 adapted recommendations Slide Sets, ESMO Courses on Medical Oncology for Medical Students, External Oncology Fellowship Opportunities, ESMO Resilience Task Force: Survey Series, ESMO-MORA Recertification Process and Requirements, ESMO Certificate of Professional Development, Professor of Cancer Research and Tony Charlton Chair, Monash University, Melbourne, Australia, Acknowledgements: Rationalizing Bureaucracy, Bibliography on Clinical Trial Procedures, ESMO Designated Centres of Integrated Oncology & Palliative Care, Palliative and Supportive Care Sessions at ESMO Congress 2022 Paris, Krebstherapie whrend der COVID-19-Pandemie, Traitement du Cancer au Cours de la Pandmie de COVID-19, Le Cure per il Cancro Durante la Pandemia da COVID-19, Cuidado del cncer durante la pandemia de COVID-19, Access to Cancer Medicines and Technologies, ESMOs Mission on Access to Cancer Medicines and Technologies, ESMO Public Policy Track and Special Sessions. Int J Med Sci (2011) 8(4):3328.10.7150/ijms.8.332 The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences. J. Gynecol. These ESMO Clinical Practice Guidelines provide recommendations on the prevention/management of dermatological toxicities. Hypersensitivity reactions associated with platinum-containing antineoplastic agents for thoracic malignancies. Clinical features and management of carboplatin-related hypersensitivity reactions in pediatric low-grade glioma. The cumulative incidence of severe carboplatin-related hypersensitivity was 1% after 15 cycles and 2% after 24 cycles, with a plateau beyond this cycle number, and 1% at >7,500 mg and 2% at >12,500 mg, with a plateau beyond this dose (Figures 1A,B ). Fu. eCollection 2017. (2009). Gynecol. doi: 10.1016/S0140-6736(03)13718-X, Pfisterer, J., Plante, M., Vergote, I., du Bois, A., Hirte, H., Lacave, A. J., et al. Keywords: The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences. Oncol. Merck KGaA, Darmstadt, Germany: Driving Innovation in Cancer Care at Europes Beating Cancer Plan in 60 minutes, World Cancer Report Updates Learning Platform, ESMO Scale for Clinical Actionability of molecular Targets (ESCAT), Recognition and Status of Medical Oncology, Status of Medical Oncology in Developing Countries, Shortages of Inexpensive, Essential Cancer Medicines, Accessibility and Availability of Medicines, Availability and Accessibility of Biomolecular Technologies in Oncology, CAREFOR, The Clinical Academic Cancer Research Forum, World Health Organization / United Nations, ESMO responses to European Union and Global Public Consultations, ESMO Facebook Roundtable: COVID-19 Vaccines and Cancer Care - The known, the unknown and the unknowable, ESMO Facebook Roundtable: COVID-19 vs Cancer - Reorganising cancer care after the first wave, ESMO Facebook Roundtable: COVID-19 vs Cancer - The future of cancer research, ESMO Facebook Roundtable: COVID-19 vs Cancer - Weighing up risks over time, COVID-19 and cancer care in the ESMO journals. Oncol. Lancet 361, 20992106. HHS Vulnerability Disclosure, Help Drug Hypersensitivity and Desensitizations: Mechanisms and New Approaches. doi: 10.1007/s00520-011-1123-y, Gomez, R., Harter, P., Lck, H. J., Traut, A., Kommoss, S., Kandel, M., et al. doi: 10.1111/j.1525-1438.2007.01063.x, Genc, D. B., Canpolat, C., and Berrak, S. G. (2012). doi: 10.1007/s00280-009-1159-6, Iwamoto, T., Hirai, H., Yamaguchi, N., Kobayashi, N., Sugimoto, H., and Tabata, T. (2014). Pediatric. This site needs JavaScript to work properly. Furthermore, Moon et al. (2009) reported a 3.54% rate of severe carboplatin-related hypersensitivity reactions, which is similar to our rate of 2.2%. The results of the trial could answer whether carboplatin hypersensitivity patients have similar chemo-responses in non-platinum regimens without compromising the efficacy of the antineoplastic regimens of these patients. Bethesda, MD 20894, Web Policies The rate of hypersensitivity to carboplatin did not differ by patient age, menopausal status, disease entity, receipt of optimal debulking, or the amount of ascites. ESMO Clinical Practice Guidelines: Supportive and Palliative Care, ESMO Clinical Practice Guidelines on Palliative Care: Advanced Care Planning, Clinical Practice Guideline Anxiety and Depression, Anaemia and Iron Deficiency in Patients With Cancer, Clinical Practice Guidelines Management of Anaemia and Iron deficiency, Clinical Practice Guidelines Bone Health in Cancer Patients, Clinical Practice Guidelines Cancer Cachexia in Adult Patients, Clinical Practice Guidelines Management of cancer pain, Clinical Practice Guidelines - Cancer-related Fatigue, Clinical Practice Guidelines Care at the End of Life, Central Venous Access in Oncology: ESMO Clinical Practice Guidelines, Management of Chemotherapy Extravasation: ESMO Clinical Practice Guidelines, Clinical Practice Guidelines Constipation in advanced cancer, Adolescents and Young Adults Working Group, ESMO SIOG Cancer in the Elderly Working Group, Examination & Accreditation Working Group, Real World Data and Digital Health Working Group, Translational Research and Precision Medicine Working Group, ESMO-Magnitude of Clinical Benefit Scale Working Group, Press and Media Affairs Committee and Social Media Working Group, ESMO-MCBS Working Group: Open Call for New Extended Members, ESMO Co-Editors-in-Chief for ESMO Journals Open Call for Members, ESMO Clinical Research Observatory Task Force (ECRO), Notification of 2022 ESMO General Assembly Vote, EnLiST ESMO Adaptation of Line of Systemic Therapy, Cancer Patient Management During the COVID-19 Pandemic, Primary brain tumours in the COVID-19 era, Gastrointestinal cancers: Hepatocellular carcinoma (HCC) in the COVID-19 era, Genitourinary cancers: Urothelial cancer of the bladder in the COVID-19 era, Genitourinary cancers: Renal cell cancer in the COVID-19 era, Genitourinary cancers: Prostate cancer in the COVID-19 era, Gynaecological malignancies: Cervical cancer in the COVID-19 era, Gynaecological malignancies: Endometrial cancer in the COVID-19 era, Haematological malignancies: DLBCL, MCL and Aggressive T-cell lymphoma in the second phase of the COVID-19 pandemic (ESMO-EHA), Haematological malignancies: Hodgkin lymphoma in the second phase of the COVID-19 pandemic (ESMO-EHA), Haematological malignancies: Indolent B-NHL in the second phase of the COVID-19 pandemic (ESMO-EHA), Haematological malignancies: Multiple myeloma in the COVID-19 era, Head and neck cancers in the COVID-19 era, COVID-19 adapted recommendations Slide Sets, ESMO Courses on Medical Oncology for Medical Students, External Oncology Fellowship Opportunities, ESMO Resilience Task Force: Survey Series, ESMO-MORA Recertification Process and Requirements, ESMO Certificate of Professional Development, Professor of Cancer Research and Tony Charlton Chair, Monash University, Melbourne, Australia, Acknowledgements: Rationalizing Bureaucracy, Bibliography on Clinical Trial Procedures, ESMO Designated Centres of Integrated Oncology & Palliative Care, Palliative and Supportive Care Sessions at ESMO Congress 2022 Paris, Krebstherapie whrend der COVID-19-Pandemie, Traitement du Cancer au Cours de la Pandmie de COVID-19, Le Cure per il Cancro Durante la Pandemia da COVID-19, Cuidado del cncer durante la pandemia de COVID-19, Access to Cancer Medicines and Technologies, ESMOs Mission on Access to Cancer Medicines and Technologies, ESMO Public Policy Track and Special Sessions.
Ping Putter Models By Year, Homes For Rent By Private Owner No Credit Check, How To Start A Dungeon In Skyblock, How Many Spears For A Wood Wall Rust, Big Agnes Rapide Sl Vs Nemo Tensor, Articles C